Market closed
Precision BioSciences/$DTIL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Precision BioSciences
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Ticker
$DTIL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
108
Website
DTIL Metrics
BasicAdvanced
$40M
3.59
$1.45
1.69
-
Price and volume
Market cap
$40M
Beta
1.69
52-week high
$19.43
52-week low
$3.61
Average daily volume
863K
Financial strength
Current ratio
9.224
Quick ratio
8.575
Long term debt to equity
44.757
Total debt to equity
46.722
Interest coverage (TTM)
-8.23%
Management effectiveness
Return on assets (TTM)
-6.38%
Return on equity (TTM)
24.44%
Valuation
Price to earnings (TTM)
3.588
Price to revenue (TTM)
0.405
Price to book
0.6
Price to tangible book (TTM)
0.6
Price to free cash flow (TTM)
-0.629
Growth
Revenue change (TTM)
43.62%
Earnings per share change (TTM)
-107.43%
3-year revenue growth (CAGR)
-13.99%
3-year earnings per share growth (CAGR)
-55.81%
What the Analysts think about DTIL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Precision BioSciences stock.
DTIL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DTIL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
DTIL News
AllArticlesVideos
Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs
Business Wire·2 days ago
Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst
Benzinga·3 weeks ago
Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Precision BioSciences stock?
Precision BioSciences (DTIL) has a market cap of $40M as of January 31, 2025.
What is the P/E ratio for Precision BioSciences stock?
The price to earnings (P/E) ratio for Precision BioSciences (DTIL) stock is 3.59 as of January 31, 2025.
Does Precision BioSciences stock pay dividends?
No, Precision BioSciences (DTIL) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Precision BioSciences dividend payment date?
Precision BioSciences (DTIL) stock does not pay dividends to its shareholders.
What is the beta indicator for Precision BioSciences?
Precision BioSciences (DTIL) has a beta rating of 1.69. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.